New pill targets rare gene faults in Hard-to-Treat cancers
NCT ID NCT07394374
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called CG001419 in adults with advanced solid tumors that have certain NTRK gene changes. The trial has two parts: first, finding a safe dose and checking for side effects; second, seeing if the drug can shrink tumors. About 42 people will take the drug daily until their disease gets worse. The goal is to learn if CG001419 is safe and effective for these cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CG001419 tablets
What this could lead to
If this works, it could offer a new treatment option for people with advanced solid tumors that have specific NTRK gene changes and have run out of standard therapies.
What could go wrong
This is an early-phase trial with only 42 participants, so results may not apply broadly. The drug may not shrink tumors or could cause side effects, and it is not yet known if it works better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS HARBORING NTRK FUSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanxi Provincial Cancer Hospital
RECRUITINGTaiyuan, China
Contact
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, China
Contact
-
The Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Sir Run Run Shaw Hospital, Affiliated to Zhejiang University School of Medicine
RECRUITINGHangzhou, China
Contact
-
West China Hospital of Sichuan University
RECRUITINGChengdu, China
Contact
-
Zhejiang Provincial Cancer Hospital
RECRUITINGHangzhou, China
Contact